Aortic Stenosis Treatment in India
Get Aortic Stenosis Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Aortic Stenosis Treatment in UAE
Aortic Stenosis Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Aortic stenosis — the progressive calcific narrowing of the aortic valve — is one of the most common valvular heart diseases in adults over 65, and when left untreated, severe symptomatic aortic stenosis carries a median survival of less than two years. Modern interventional cardiology now offers both surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR/TAVI), with procedural success rates exceeding 95% at high-volume centres. GAF Healthcare connects international patients to JCI- and NABH-accredited hospitals in India and JCI- and DHA-accredited hospitals in Dubai and Abu Dhabi, delivering world-class aortic valve care at a fraction of Western costs, with end-to-end coordination from first consultation to post-discharge follow-up.
Hospital Stay: 5–10 days (TAVR: 3–5 days; SAVR: 7–10 days) • Total Stay in Country (Fit-to-Fly): 3–6 weeks (TAVR patients cleared earlier at ~3 weeks; SAVR patients typically require 5–6 weeks before long-haul flight) • Success Rate: 95–98% procedural success at high-volume partner centres
What Is It?
Aortic stenosis (AS) is the pathological obstruction of left ventricular outflow caused by progressive thickening, calcification, and fusion of the aortic valve leaflets, most commonly degenerative (senile calcific) in origin, though rheumatic and congenital bicuspid aortic valve disease remain significant aetiologies in South Asian and Middle Eastern populations. As the valve orifice narrows — severe AS is defined as an aortic valve area (AVA) ≤1.0 cm², a mean pressure gradient ≥40 mmHg, or a peak aortic jet velocity ≥4.0 m/s on Doppler echocardiography — the left ventricle compensates through concentric hypertrophy, eventually leading to diastolic dysfunction, reduced coronary flow reserve, and, in end-stage disease, systolic failure. The classical clinical triad of angina, syncope, and heart failure (Heyde's syndrome being a notable associated finding) marks the inflection point at which annual mortality without intervention approaches 25–50%.
The haemodynamic burden of severe AS creates a fixed afterload mismatch that no pharmacological agent can adequately address; vasodilators may precipitate haemodynamic collapse and no medication alters disease progression or improves survival in symptomatic severe AS. International guidelines from the ACC/AHA (2021) and ESC/EACTS (2021) therefore recommend prompt valve intervention — Class I, Level B — for all symptomatic patients with severe AS. Risk stratification is performed using the Society of Thoracic Surgeons (STS) Predicted Risk of Mortality (PROM) score and the EuroSCORE II, which guide the heart team's choice between SAVR and TAVR.
At GAF Healthcare's partner institutions in India and the UAE, dedicated structural heart programmes operate multidisciplinary Heart Teams comprising interventional cardiologists, cardiac surgeons, cardiac anaesthesiologists, imaging specialists, and valve clinic nurses — mirroring the organisational model validated at centres such as the Cleveland Clinic and the German Heart Centre. These programmes perform hundreds of TAVR and SAVR cases annually, giving them the volume-outcome relationships that directly correlate with lower 30-day mortality and complication rates.
Candidates
• ELIGIBILITY — SYMPTOMATIC SEVERE AS: Patients with AVA ≤1.0 cm² (indexed AVA ≤0.6 cm²/m²) AND at least one of: angina on exertion, unexplained syncope or pre-syncope, or NYHA Class II–IV dyspnoea attributable to AS
• ASYMPTOMATIC SEVERE AS WITH HIGH-RISK FEATURES: LVEF <50%, very severe AS (Vmax ≥5 m/s or mean gradient ≥60 mmHg), rapid haemodynamic progression (increase in Vmax ≥0.3 m/s/year), or an abnormal exercise stress test
• MODERATE AS WITH CONCURRENT CARDIAC SURGERY: Patients requiring CABG or other open cardiac surgery who have moderate AS (AVA 1.0–1.5 cm²)
• REQUIRED PRE-PROCEDURAL DIAGNOSTICS:
- Transthoracic Echocardiography (TTE): Primary valve assessment; AVA by continuity equation, gradients, LVEF, and annulus sizing
- Transesophageal Echocardiography (TEE): Annular measurement, leaflet morphology, bicuspid vs. tricuspid classification
- Multi-Slice CT (MSCT / Cardiac CT): Mandatory for TAVR — annular sizing, iliofemoral access route assessment, coronary ostia heights, calcium scoring (Agatston score)
- Coronary Angiography (or CT-Coronary Angiography): Rule out significant CAD requiring concomitant revascularisation
- Right and Left Heart Catheterisation: When non-invasive data is inconclusive (low-flow, low-gradient AS)
- Dobutamine Stress Echocardiography (DSE): Differentiates true severe AS from pseudo-severe AS in low-flow states
- Blood Panel: CBC, renal function (eGFR — critical for contrast load planning), coagulation studies, HbA1c, thyroid function
- 6-Minute Walk Test & Frailty Assessment (Fried Frailty Index, KATZ ADL score): Integral to TAVR candidacy
• RELATIVE CONTRAINDICATIONS FOR TAVR: Annulus diameter outside device IFU range (<18 mm or >29 mm on MSCT), severe iliofemoral disease precluding transfemoral access (alternative access: transapical, transaortic, transsubclavian, transcaval evaluated), absence of suitable landing zone due to heavy subannular calcification
• RELATIVE CONTRAINDICATIONS FOR SAVR: STS-PROM ≥8% (high surgical risk, favours TAVR), severe COPD (FEV1 <50% predicted), severe renal failure (eGFR <30 mL/min/1.73m²), prior mediastinal radiation, porcelain aorta
• ABSOLUTE CONTRAINDICATION FOR ANY VALVE INTERVENTION: Life expectancy <12 months from non-cardiac comorbidity, or where valve intervention would not improve quality of life
Procedure
TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR / TAVI) — MINIMALLY INVASIVE GOLD STANDARD FOR INTERMEDIATE-TO-HIGH RISK:
TAVR has rapidly expanded from a salvage procedure for inoperable patients (PARTNER 1B, 2011) to the preferred approach for intermediate-risk (PARTNER 2A, SURTAVI) and, increasingly, low-risk patients (PARTNER 3, Evolut Low Risk, 2019). A bioprosthetic valve — crimped onto a delivery catheter — is deployed within the native diseased leaflets, which are pushed aside (not excised). The procedure is performed under fluoroscopic and echocardiographic (TEE or ICE) guidance. Access routes include:
• Transfemoral (TF-TAVR): Preferred route (~90% of cases); 14–16Fr sheath through the femoral artery; performed under conscious sedation or general anaesthesia; hospital stay 2–4 days; fastest recovery
• Alternative Access (when TF unavailable): Transapical (TA), Transaortic (TAo), Transsubclavian/Transaxillary, or Transcaval (TC) — each requiring cardiac surgery support
Approved TAVR platforms available at GAF partner centres:
• Edwards SAPIEN 3 / SAPIEN 3 Ultra (balloon-expandable; sizes 20–29 mm)
• Medtronic Evolut PRO+ / Evolut FX (self-expanding; sizes 23–34 mm; repositionable)
• Boston Scientific ACURATE neo2 (self-expanding; available in select centres)
Key TAVR metrics at high-volume GAF partner centres: procedural success >97%, 30-day stroke rate <2%, permanent pacemaker implantation rate 5–25% (device-dependent), paravalvular leak (moderate-severe) <3%.
SURGICAL AORTIC VALVE REPLACEMENT (SAVR) — STANDARD OF CARE FOR LOW-TO-INTERMEDIATE RISK:
SAVR remains the Class I recommendation for low-risk patients (STS-PROM <4%, age <65–70) and is performed under cardiopulmonary bypass (CPB) with cardioplegic arrest. The diseased valve is excised, the annulus is debrided of calcium, and a prosthetic valve is implanted under direct vision. Options:
• Bioprosthetic (Tissue) Valves: Pericardial (e.g., Edwards Magna Ease, St. Jude Trifecta, Sorin Perceval S sutureless) — no long-term anticoagulation required; preferred in patients >65 years or those with anticoagulation contraindications. Haemodynamic performance assessed by effective orifice area (EOA) and prosthesis-patient mismatch (PPM) index.
• Mechanical Valves: On-X, St. Jude Regent — superior durability; mandatory lifelong warfarin (target INR 1.5–2.0 for On-X aortic position per PROACT trial); preferred in patients <60 years without anticoagulation contraindications.
• Sutureless / Rapid-Deployment Valves (Perceval S, Intuity Elite): Reduce aortic cross-clamp time; particularly advantageous in redo surgery, small annuli, and combined procedures.
• Ross Procedure (Pulmonary Autograft): Autologous pulmonary valve translocated to aortic position; gold standard for patients <50 years requiring a living, growing valve — offers potential lifelong freedom from re-intervention in young patients.
• Minimally Invasive SAVR (MIS-SAVR): Upper hemisternotomy or right anterior minithoracotomy approach; reduced blood loss, shorter ICU stay, faster return to activity vs. conventional sternotomy; available at select GAF partner centres with dedicated structural heart programmes.
BALLOON AORTIC VALVULOPLASTY (BAV) — BRIDGE OR PALLIATIVE:
Percutaneous BAV dilates the stenotic valve using a balloon catheter; provides only temporary palliation (restenosis within 6–12 months in >80% of cases). Current indications are strictly limited to: (1) haemodynamic stabilisation as a bridge to TAVR or SAVR in cardiogenic shock; (2) diagnostic evaluation (improvement post-BAV predicts benefit from definitive valve replacement); (3) palliation in patients who are not candidates for definitive intervention.
MEDICAL MANAGEMENT (ADJUNCTIVE — NOT CURATIVE):
No medication modifies AS progression. Statins (rosuvastatin, atorvastatin) do not slow calcification (SEAS, ASTRONOMER trials). Management targets comorbidities: diuretics for congestion (cautious use — excessive preload reduction dangerous), beta-blockers for rate control in AF, ACE inhibitors/ARBs used cautiously in LV dysfunction. Anticoagulation with VKA or DOAC for concomitant AF per CHA₂DS₂-VASc score. Post-TAVR, dual antiplatelet therapy (DAPT: aspirin 75–100 mg + clopidogrel 75 mg for 3–6 months, then aspirin monotherapy) per POPular-TAVI trial findings.
Cost of Aortic Stenosis Treatment: India vs. UAE
The cost of aortic stenosis treatment — whether TAVR or SAVR — varies significantly depending on the chosen destination, the specific procedure, the prosthesis selected, and the patient's clinical complexity. India offers the most competitive pricing globally, with costs 60–75% lower than equivalent procedures in the United States or Western Europe, while maintaining comparable clinical outcomes at JCI- and NABH-accredited institutions. The UAE (Dubai and Abu Dhabi) positions itself as a premium-tier destination with internationally trained specialists, luxury hospital infrastructure, and streamlined access for patients from the Middle East, Africa, and Europe — at costs approximately 30–50% lower than the US. Both destinations include the prosthetic valve, implant, procedural fees, anaesthesia, standard ICU stay, ward stay, nursing care, basic medications, and pre-discharge echocardiogram. MSCT planning scans, coronary angiography, and extended ICU stays are typically billed separately. GAF Healthcare provides itemised, transparent cost estimates before any financial commitment is made.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $7,000 – $18,000 | ~57% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $18,000 – $40,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (Weeks 1–3 before travel):
• Patient submits medical records (echocardiogram reports, cardiac catheterisation, CT scans, blood work) to GAF Healthcare's medical coordination team
• GAF's partner cardiologist/cardiac surgeon conducts a teleconsultation and performs preliminary risk stratification using STS-PROM and EuroSCORE II
• Heart Team decision: TAVR vs. SAVR vs. combined procedure recommended in writing
• GAF issues a formal Invitation Letter for e-Medical Visa (India) or assists with UAE medical visit visa
• Provisional procedure date confirmed; pre-admission instructions issued (medications to hold — antiplatelet agents, anticoagulants, metformin; NPO guidelines)
PHASE 2 — ARRIVAL & PRE-OPERATIVE WORKUP (Days 1–3 in country):
• GAF airport meet-and-greet; transfer to partner hospital or pre-arranged accommodation
• Cardiology admission; repeat TTE, 12-lead ECG, chest X-ray
• MSCT aortic annulus sizing and access-route planning (TAVR patients)
• TEE under sedation for annular morphology and bicuspid classification
• Coronary angiography if not performed within 3 months
• Frailty assessment, physiotherapy baseline assessment, anaesthesia pre-assessment
• Multidisciplinary Heart Team review and final procedure confirmation
• Patient and family counselling; informed consent obtained in patient's language (GAF translator present)
PHASE 3 — THE PROCEDURE:
• TAVR: Performed in hybrid catheterisation laboratory or cardiac operating theatre; duration 60–120 minutes; conscious sedation or general anaesthesia; transfemoral access in majority; real-time TEE or intracardiac echo (ICE) guidance throughout deployment; post-deployment aortography confirms valve position, coronary patency, and paravalvular leak assessment
• SAVR (Conventional): 4–6 hours under general anaesthesia; median sternotomy or minimally invasive approach; cardiopulmonary bypass; excision of diseased valve, annular decalcification, prosthesis sizing and implantation; separation from bypass; TEE confirmation of valve function before chest closure
• Immediate post-procedure: Transfer to cardiac ICU; haemodynamic monitoring; continuous ECG monitoring for conduction disturbances (LBBB, complete heart block — particularly post-TAVR); early extubation protocol for TAVR (typically within 1–4 hours)
PHASE 4 — IN-HOSPITAL RECOVERY:
• Day 1–2: ICU monitoring; haemodynamic stability confirmed; pacemaker threshold testing if temporary pacing wire placed; ambulation begins for TAVR patients as early as Day 1
• Day 3–5 (TAVR): Step-down to cardiac ward; TTE to assess prosthetic valve gradients, paravalvular regurgitation, and LV function; 48-hour Holter monitor to screen for occult AF or conduction disturbances; DAPT initiated per protocol
• Day 5–7 (SAVR): Sternal wound check; respiratory physiotherapy (incentive spirometry critical); removal of chest drains; transthoracic echo confirming prosthesis function; INR monitoring if mechanical valve implanted
• Day 7–10 (SAVR): Stepwise mobilisation; staircase climb test; dietitian review; cardiac rehabilitation plan issued
PHASE 5 — POST-DISCHARGE IN-COUNTRY RECOVERY:
• TAVR patients: 2–3 additional weeks in country (local hotel or serviced apartment arranged by GAF); outpatient cardiology review at 7 days post-discharge including TTE, wound check, ECG
• SAVR patients: 3–4 additional weeks; sternal precautions counselled (no lifting >5 kg, no driving for 6 weeks); wound clinic visit at 10–14 days post-discharge
• Milestone: Patient declared 'fit-to-fly' by the treating cardiologist based on haemodynamic stability, absence of significant pacemaker dependency, healed access site/wound, and absence of post-procedural complications (stroke, significant paravalvular leak, pericardial effusion on echo)
PHASE 6 — REPATRIATION & LONG-TERM FOLLOW-UP:
• GAF coordinates medical clearance letter and in-flight medical notes
• Escort or medical travel companion arranged if required
• Comprehensive discharge summary in English + patient's language forwarded to home cardiologist
• Remote follow-up teleconsultation at 30 days, 3 months, and 12 months with GAF partner cardiologist
• Annual TTE for bioprosthetic valve surveillance; INR clinic integration for mechanical valve patients
Risks & Considerations
Aortic valve intervention — whether TAVR or SAVR — is a high-complexity cardiac procedure and carries well-characterised risks that every patient must understand prior to consenting. For TAVR, the most clinically significant risks include: stroke or transient ischaemic attack (TIA) — reported in 2–4% of patients within 30 days, with the highest risk in the first 24–48 hours post-implantation due to embolic debris from calcified leaflets; this risk is partially mitigated by the use of cerebral embolic protection devices (e.g., Sentinel device) at select centres. Permanent pacemaker implantation is required in 5–25% of TAVR patients (higher with self-expanding valves and deeper implantation depth) due to injury to the His-Purkinje conduction system. Paravalvular regurgitation (PVR), even when mild-to-moderate, is associated with excess late mortality and mandates careful post-deployment assessment with TEE and aortography. Vascular access complications — femoral artery dissection, haematoma, pseudoaneurysm — occur in 2–6% and are managed percutaneously in most cases. Coronary obstruction is rare (<1%) but catastrophic; risk is highest in patients with low coronary ostia heights (<10 mm) or bulky calcified native leaflets — identified and mitigated by careful pre-procedural MSCT analysis. Annular rupture is an uncommon but potentially fatal complication (risk <1%) associated with heavy annular calcification and balloon over-sizing.
For SAVR, principal risks include: 30-day mortality of 1–3% in low-risk patients (STS-PROM matched); stroke 1–3%; deep sternal wound infection 0.5–2% (higher in diabetic patients or those with prior sternotomy); low cardiac output syndrome in patients with severely impaired pre-operative LV function; acute kidney injury requiring temporary dialysis in 2–5%; prolonged mechanical ventilation; and new-onset atrial fibrillation (25–40%), which typically responds to medical cardioversion but may require anticoagulation. Prosthesis-patient mismatch (PPM) — where the implanted valve EOA is inadequate for the patient's body surface area — can negate haemodynamic benefit and should be pre-empted by careful annular sizing and prosthesis selection. Late risks common to both procedures include structural valve deterioration (SVD) of bioprostheses — historically at 10–15 years, though newer generation pericardial valves demonstrate improved durability — and valve thrombosis (rare, <1%). Patients with mechanical prostheses carry lifelong bleeding risk from anticoagulation (annual major bleeding ~1–2%) and thromboembolic risk from subtherapeutic INR. All risks are discussed in detail during GAF Healthcare's pre-procedure multidisciplinary consultation, with decisions individualised to each patient's anatomy, comorbidities, and life expectancy.
Top Hospitals for Aortic Stenosis Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Fortis Memorial Research Institute
Gurgaon, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Top Doctors for Aortic Stenosis Treatment
Internationally trained specialists in Cardiology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Niranjan Hiremath
MBBS, MS (General Surgery), MCh (Cardiothoracic Surgery), FVES (Vascular Surgery), FACS, FCAS, FICE
Cardiac and Aortic Surgeon
Apollo Hospitals, Bannerghatta Road, Bengaluru, India
14+ Yearsof experience
Dr. Niranjan Hiremath is an internationally trained Cardiac and Aortic Surgeon serving as Surgical Lead of the Aortic Center of Excellence at Apollo Hospitals, Bannerghatta Road, Bengaluru. With over 14 years of clinical experience, he is widely recognized for his expertise in complex aortic pathology, structural heart surgery, and hybrid surgical approaches. His training encompasses advanced fellowships in Aortic, Cardiac, and Endovascular Surgery,… Read more
Dr. Krishna S Iyer
MBBS, MS (Surgery), M.Ch (Cardiothoracic Surgery), Fellowship in Infant Cardiac Surgery
Pediatric Cardiac Surgeon
Fortis Escorts Heart Institute, New Delhi, India
35+ Yearsof experience
Dr. Krishna S Iyer is one of India's most experienced and internationally recognised pediatric cardiac surgeons. As Executive Director of Pediatric and Congenital Heart Surgery at Fortis Escorts Heart Institute in Okhla, New Delhi, he has devoted his career to giving children with congenital heart disease — some of the most complex and delicate patients in all of medicine — the best possible chance at a full life. After his medical training, Dr. Iyer… Read more
Dr. Devi Shetty
MBBS, MS (General Surgery), MCh (Cardiothoracic Surgery), Fellowship in Cardiac Surgery
Cardiac Surgeon
Narayana Health, Bengaluru, India
38+ Yearsof experience
Dr. Devi Prasad Shetty is one of the most respected and widely recognised cardiac surgeons in the world. He is the founder and chairman of Narayana Health, a hospital chain that has redefined what affordable, high-quality cardiac care looks like — not only in India, but globally. Early in his career, Dr. Shetty trained at Guy's Hospital in London, one of the oldest teaching hospitals in Britain. He later served as personal physician to Mother Teresa, an… Read more
Dr. Naresh Trehan
MBBS, MS (General Surgery), Fellowship in Cardiothoracic Surgery
Cardiothoracic Surgeon
Medanta – The Medicity, Gurgaon, India
40+ Yearsof experience
Dr. Naresh Trehan is widely regarded as one of the most accomplished cardiovascular and cardiothoracic surgeons of his generation. With more than four decades of clinical practice spanning India and the United States, he has performed over 48,000 cardiac surgeries and has consistently ranked among the best heart surgeons in Asia. Born and educated in India, Dr. Trehan completed his advanced surgical training at New York University Medical Center, where he… Read more
Dr. Z S Meharwal
MBBS, MS (Surgery), MCh (Cardiothoracic Surgery), MNAMS
Cardiothoracic Surgeon
Fortis Escorts Heart Institute, New Delhi, India
30+ Yearsof experience
Dr. Z S Meharwal is part of the founding team of doctors at Fortis Escorts Heart Institute in Okhla, New Delhi, one of India's most respected cardiac centres. With more than 30 years of experience in cardiac surgery and over 30,000 surgeries to his credit — including many of the most complex heart operations performed in the country — he stands as one of the most accomplished cardiothoracic surgeons of his generation. Dr. Meharwal is a pioneer in many new… Read more
Frequently Asked Questions — Aortic Stenosis Treatment
The total cost of aortic stenosis treatment depends on the specific procedure chosen — TAVR (transcatheter) or SAVR (surgical) — the prosthetic valve selected, and the patient's individual clinical complexity. In India, at JCI- and NABH-accredited cardiac centres, the all-inclusive cost for TAVR typically ranges from USD 10,000 to USD 18,000, while conventional surgical aortic valve replacement (SAVR) ranges from USD 7,000 to USD 14,000. These figures include the prosthetic valve and implant materials, cardiac ICU stay, ward stay, standard medications, anaesthesia, and a pre-discharge echocardiogram. In the UAE (Dubai and Abu Dhabi), at JCI- and DHA-accredited institutions, the equivalent cost ranges from USD 22,000 to USD 40,000 for TAVR and USD 18,000 to USD 30,000 for SAVR, reflecting the premium infrastructure, operating costs, and specialist fees of the Gulf region. Both destinations offer a cost saving of 50–75% compared to equivalent procedures in the United States (where TAVR alone exceeds USD 80,000–100,000) or Western Europe. GAF Healthcare provides a fully transparent, itemised cost estimate specific to your diagnostic profile before any financial commitment — covering all procedural, hospital, and associated non-medical logistics costs, with no hidden facilitation charges to the patient.
The duration of in-country stay before you are medically cleared for international air travel depends primarily on whether you undergo TAVR or surgical aortic valve replacement (SAVR), and on your individual post-procedural recovery course. For TAVR via the transfemoral route, the typical hospital stay is 3–5 days. Most TAVR patients who have an uncomplicated procedure — no permanent pacemaker requirement, no neurological event, stable haemodynamics, and a healed femoral access site — are declared fit-to-fly by the treating cardiologist approximately 2–3 weeks after the procedure. This allows time for a 7-day post-discharge outpatient review with echocardiogram and ECG, and ensures that any delayed conduction disturbances or early valve thrombosis have been identified. For SAVR, the hospital stay is 7–10 days, and the sternal wound, pleural healing, and volume status require a longer period of monitoring. SAVR patients are typically cleared for long-haul international flight 5–6 weeks post-procedure. Patients with a permanent pacemaker implanted post-TAVR require a device check at 4–6 weeks before air travel. Patients with new-onset atrial fibrillation post-SAVR require therapeutic anticoagulation and rhythm stability before flying. GAF Healthcare's treating cardiologist issues a formal medical fitness-to-fly certificate, along with an in-flight medical briefing note for the airline, before your departure is confirmed. We strongly advise against self-discharge or premature travel, as the haemodynamic changes at cabin altitude and the risk of deep vein thrombosis on long-haul flights are clinically significant in the early post-operative period.
At GAF Healthcare's high-volume partner centres in India and the UAE, procedural success rates for aortic stenosis intervention are 95–98%, consistent with outcomes reported by leading global structural heart programmes. For TAVR specifically, 'device success' — defined by the Valve Academic Research Consortium-2 (VARC-2) criteria as successful vascular access, delivery, and deployment of the valve in the correct anatomical position, with only trace or mild paravalvular regurgitation and a post-procedural mean gradient of less than 20 mmHg — is achieved in over 97% of procedures at our partner centres. The 30-day all-cause mortality for isolated TAVR in low-to-intermediate risk patients at these institutions is below 2%, mirroring landmark trial data from PARTNER 3 and Evolut Low Risk. For surgical aortic valve replacement (SAVR) in low-risk patients (STS-PROM below 4%), 30-day mortality is 1–2%. At 1 year, freedom from all-cause mortality post-TAVR exceeds 90% in intermediate-risk cohorts, and post-SAVR, 10-year survival with a tissue bioprosthesis is approximately 60–70% (heavily influenced by patient age and comorbidities rather than valve-related failure). Structural valve deterioration requiring re-intervention is rare within the first 8–10 years for modern pericardial bioprostheses. It is important to understand that 'success rate' encompasses both the procedural technical success and longer-term haemodynamic and clinical outcomes — both of which are systematically tracked and reported by GAF's partner institutions through mandatory institutional quality registries and follow-up programmes. Your specific outcome probability will be individualised by the treating Heart Team based on your STS-PROM score, EuroSCORE II, MSCT anatomy, frailty assessment, and comorbidity profile during the pre-procedural teleconsultation with GAF Healthcare.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end medical travel coordination that extends well beyond clinical referral, ensuring that patients and their families experience the least possible stress during what is invariably an emotionally and logistically demanding journey.
VISA & ENTRY DOCUMENTATION — INDIA: GAF Healthcare's coordination team prepares and submits the e-Medical Visa application on the patient's behalf through the Indian government's online portal (indianvisaonline.gov.in). The e-Medical Visa for India permits three entries within 60 days and is granted to citizens of 156 eligible countries within 3–5 working days. GAF provides the mandatory hospital Invitation Letter from the treating institution, which is a required supporting document for the application. Up to two medical attendant e-Visas (e-MV) are simultaneously arranged for accompanying family members.
VISA & ENTRY DOCUMENTATION — UAE: Citizens of over 120 countries receive visa-on-arrival or visa-free entry to the UAE for 30–90 days, covering the full treatment and recovery period for the majority of international patients. For nationalities requiring a pre-arranged medical visit visa, GAF Healthcare liaises directly with the host hospital's international patient department to obtain the necessary approval from the Federal Authority for Identity and Citizenship (ICA). Dubai Health Authority (DHA) registration of the treating physicians ensures regulatory compliance for all procedures.
AIRPORT & GROUND TRANSFERS: A dedicated GAF representative meets patients at the arrival terminal — Mumbai, Delhi, Chennai, Bengaluru, Dubai, or Abu Dhabi airports — holding a personalised nameplate. Private, air-conditioned vehicles with a trained medical escort are provided for all hospital transfers. Wheelchair assistance and oxygen support during ground transport are arranged in advance for patients with severe symptomatic AS who may be haemodynamically compromised on arrival.
CLINICAL TRANSLATION & INTERPRETATION: GAF maintains a roster of certified medical interpreters in Arabic, Russian, Swahili, French, Amharic, Uzbek, Bengali, and other languages. An interpreter is present at all key clinical encounters — Heart Team discussions, informed consent, post-operative de-briefing, and discharge counselling — to ensure complete comprehension. All discharge documentation is translated into the patient's language.
ACCOMMODATION FOR ATTENDANTS: During the patient's in-hospital stay, GAF arranges accommodation for up to two family attendants at partner guesthouses, serviced apartments, or hospital-adjacent hotels at negotiated rates. During the post-discharge in-country recovery phase, fully furnished serviced apartments with dedicated cooking facilities (important for patients on specific cardiac diets) are arranged within 5–15 minutes of the treating hospital. GAF's on-ground patient liaison officer conducts daily check-in calls and escorts attendants to outpatient review appointments.
FINANCIAL TRANSPARENCY: A fully itemised cost estimate covering all anticipated medical and non-medical expenses is provided in writing before the patient travels. GAF facilitates wire transfer, international card payments, and — in select partner hospitals — deferred payment structures. No hidden facilitation fees are charged to the patient; GAF's model is hospital-partnership based.
Patients Also Explore
Other treatments commonly sought by patients considering Aortic Stenosis Treatment.
Breast Cancer Treatment
Cancer Care
Lung Cancer Treatment
Cancer Care
Brain Tumor Surgery
Neurology
Deep Brain Stimulation
Neurology